Sugi Predict

Sugi Predict / Compounds / Terminolic Acid

Terminolic Acid

Terminolic Acid

SCHEMBL1048239

CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@]43C)[C@@H]2C1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 7/20 0.77
▸ ALOX5 P09917 2/20 0.77
▸ USP2 O75604 3/20 0.71
▸ CYP3A4 P08684 3/20 0.68
▸ TDP1 Q9NUW8 1/20 0.68
▸ KDM4E B2RXH2 1/20 0.68
▸ ALDH1A1 P00352 1/20 0.68
▸ TP53 P04637 1/20 0.68
▸ MAPT P10636 1/20 0.68
▸ HPGD P15428 1/20 0.68
▸ HSD17B10 Q99714 1/20 0.68
▸ F3 P13726 2/20 0.66
▸ LMNA P02545 1/20 0.66
▸ USP7 Q93009 1/20 0.66
▸ SLCO1B3 Q9NPD5 1/20 0.66
▸ SLCO1B1 Q9Y6L6 1/20 0.66
▸ AKR1B10 O60218 1/20 0.65
▸ PYGM P11217 1/20 0.65
▸ AKR1B1 P15121 1/20 0.65
▸ PTPN2 P17706 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terminolic Acid SCHEMBL5796274 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
Terminolic Acid SCHEMBL5796424 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
Terminolic Acid SCHEMBL5798233 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
Terminolic Acid SCHEMBL5796268 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
Terminolic Acid SCHEMBL2099327 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
Terminolic Acid SCHEMBL27133066 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
Terminolic Acid SCHEMBL26940223 1.00 PTPN1 (0.77) PTPN1ALOX5USP2CYP3A4TDP1
SCHEMBL26940214 0.88 PTPN1 (0.63) PTPN1ALOX5USP2CYP3A4TDP1
Arjunolic Acid SCHEMBL24135094 0.87 PTPN1 (1.00) PTPN1ALOX5USP2CYP3A4TP53
Arjunolic Acid SCHEMBL18420183 0.87 PTPN1 (1.00) PTPN1ALOX5USP2CYP3A4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360071-A1 AGENT FOR INDUCING CILIUM MED R&D CO LTD (JP) 2025-11-27 — — US claimed
US-20250360071-A1 AGENT FOR INDUCING CILIUM MED R&D CO LTD (JP) 2025-11-27 — — US disclosed
US-20220291237-A1 Gene Expression Inflammatory Age and Its Uses Edifice Health, Inc. (US) 2022-09-15 — — US disclosed
US-20110020226-A1 PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS NORDIC VACCINE TECHNOLOGY A/S 2011-01-27 — — US disclosed
US-7713942-B2 Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides NORDIC VACCINE TECHNOLOGY A/S (DK) 2010-05-11 — — US disclosed
EP-2011517-A1 Polynucleotide binding complexes comprising sterols and saponin Nordic Vaccine Technology A/S (DK) 2009-01-07 — — EP disclosed
EP-1377320-B1 POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS NORDIC VACCINE TECHNOLOGY AS (DK) 2008-10-01 — — EP disclosed
US-20060235078-A1 Insulin secretion potentiator USE-TECHNO CORPORATION 2006-10-19 — — US disclosed
EP-1674089-A1 ACCELERATOR FOR INITIAL INSULIN SECRETION Use-Techno Corporation (JP) 2006-06-28 — — EP disclosed
WO-2006064583-A1 TERPENE, METHOD FOR DETERMINING ITS BLOOD CONCENTRATION, AND METHOD FOR ANALYZING ITS PHARMACOKINETICS USE-TECHNO CORPORATION (JP) 2006-06-22 — — WO disclosed
WO-2006054370-A1 GLUCONEOGENESIS INHIBITING AGENT USE-TECHNO CORPORATION (JP) 2006-05-26 — — WO disclosed
US-20050143464-A1 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts USE-TECHNO CORPORATION 2005-06-30 — — US disclosed
EP-1409009-A1 THERAPEUTICAL VACCINATION Nordic Vaccine Technology A/S (DK) 2004-04-21 — — EP disclosed
EP-1377320-A2 POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS Nordic Vaccine Technology A/S (DK) 2004-01-07 — — EP disclosed
WO-2002102407-A1 THERAPEUTICAL VACCINATION NORDIC VACCINE TECHNOLOGY A/S (DK) 2002-12-27 — — WO disclosed
WO-2002080981-A2 POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS NORDIC VACCINE TECHNOLOGY A/S (DK) 2002-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143464-A1 With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts GPR119, IRS1, AMY1A PTPN1 1873/4885ALOX5 511/4885USP2 3824/4885
US-20110020226-A1 PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS LSS, SNRPE, HLA-C PTPN1 2398/4885ALOX5 651/4885USP2 4730/4885
US-20060235078-A1 Insulin secretion potentiator IAPP, GPR119, IRS1 PTPN1 1481/4885ALOX5 3951/4885USP2 1979/4885
US-20250360071-A1 AGENT FOR INDUCING CILIUM OSBPL3, OSBP, OSBPL8 PTPN1 4338/4885ALOX5 2439/4885USP2 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.